A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Summary

The goal of this study is to use magnetic resonance venography with long-circulating gadolinium-based contrast agent and direct thrombus imaging for quantitative evaluation of DVT volume in a multicenter, clinical trial setting. Inter- and intra-observer variability assessments were conducted, and reproducibility of the protocol was determined.

Abstract

We evaluated a magnetic resonance venography (MRV) approach with gadofosveset to quantify total thrombus volume changes as the principal criterion for treatment efficacy in a multicenter randomized study comparing edoxaban monotherapy with a heparin/warfarin regimen for acute, symptomatic lower extremities deep vein thrombosis (DVT) treatment. We also used a direct thrombus imaging approach (DTHI, without the use of a contrast agent) to quantify fresh thrombus. We then sought to evaluate the reproducibility of the analysis methodology and applicability of using 3D magnetic resonance venography and direct thrombus imaging for the quantification of DVT in a multicenter trial setting. From 10 randomly selected subjects participating in the edoxaban Thrombus Reduction Imaging Study (eTRIS), total thrombus volume in the entire lower extremity deep venous system was quantified bilaterally. Subjects were imaged using 3D-T1W gradient echo sequences before (direct thrombus imaging, DTHI) and 5 min after injection of 0.03 mmol/kg of gadofosveset trisodium (magnetic resonance venography, MRV). The margins of the DVT on corresponding axial, curved multi-planar reformatted images were manually delineated by two observers to obtain volumetric measurements of the venous thrombi. MRV was used to compute total DVT volume, whereas DTHI was used to compute volume of fresh thrombus. Intra-class correlation (ICC) and Bland Altman analysis were performed to compare inter and intra-observer variability of the analysis. The ICC for inter and intra-observer variability was excellent (0.99 and 0.98, p <0.001, respectively) with no bias on Bland-Altman analysis for MRV images. For DTHI images, the results were slightly lower (ICC = 0.88 and 0.95 respectively, p <0.001), with bias for inter-observer results on Bland-Altman plots. This study showed feasibility of thrombus volume estimation in DVT using MRV with gadofosveset trisodium, with good intra- and inter-observer reproducibility in a multicenter setting.

Introduction

Venous thromboembolism (VTE) affects 300,000-600,000 individuals in the United States every year¹. Deep vein thrombosis (DVT) is the most common presentation of VTE, and most commonly affects the calf, thigh or pelvic veins. The diagnosis, management, and follow-up of subjects with DVT cannot be based solely on clinical examinations, since the signs and symptoms of this disease are non-specific^2,3. While blood tests (such as D-dimer) can help rule out the diagnosis of DVT, imaging is required to establish the presence of DVT⁴. Compression ultrasound (CUS) is currently the most commonly used imaging test in the diagnosis of suspected acute DVT. CUS is inexpensive and has high sensitivity and specificity to detect acute DVT⁵. However, CUS cannot reliably assess the deep veins in the pelvis⁶. Additionally, CUS cannot directly quantify thrombus volume and composition, which are important when distinguishing between acute DVT (a potential source of pulmonary embolism (PE)) and chronic DVT (less likely to embolize) and for evaluation of therapeutic efficacy⁷.

Unlike computed tomography (CT), magnetic resonance imaging (MRI) does not deliver ionizing radiation, and is therefore suitable for serial examinations to evaluate thrombus evolution or regression. Compared with CUS, MRI can detect pelvic DVT and can more precisely define proximal (popliteal vein and above) and distal leg (below popliteal vein) DVT⁸, to better assess the risk of PE. MRI can characterize thrombus age and organization, and may help differentiate acute from chronic DVT^9-11 (refs updated). Quantification of thrombus volume, an important metric to assess the disease evolution and response to treatment, is feasible with MR imaging. Current magnetic resonance venography protocols are performed after injection of gadolinium (Gd) based contrast agents¹². These are small molecular weight molecules that extravasate quickly after injection, and require careful timing to capture the venous enhancement phase needed to correctly visualize the thrombus^13,14.

A proof-of-concept study, edoxaban Thrombus Reduction Imaging Study (eTRIS), utilizing an open label design, investigated the efficacy and safety of edoxaban 90 mg once a day for 10 days, followed by edoxaban 60 mg once a day in the treatment of acute, symptomatic DVT (ClinicalTrials.gov Identifier: NCT01662908). eTRIS addresses whether edoxaban monotherapy, without concomitant low molecular weight heparin (LMW heparin) at the time of treatment initiation, is more effective than standard treatment with LMW heparin/warfarin therapy in subjects with DVT, as assessed by the percent (%) change from baseline in thrombus volume/size (measured by MRI) at Day 14-21.

Another goal of eTRIS was to develop and validate a straightforward MR venography (MRV) image acquisition and analysis protocol for the quantification of thrombus volume in DVT. To overcome some challenges faced by current MRV protocols in multicenter settings, we utilized a recently FDA-approved, long-circulating, gadolinium-based blood pool contrast agent (gadofosveset trisodium). Compared to the use of extracellular Gd-based chelates (e.g., Gd-DTPA) for MRV, gadofosveset has a significantly longer circulation time, which allows use of a simpler MR acquisition scheme, without any timing of acquisitions. Gadofosveset trisodium is a blood pool MRI contrast agent that circulates for 2-3 hr after intravenous injection^15,16. Its safety profile is similar to those of traditional extravascular extracellular MRI contrast agents¹⁷. It allows steady-state imaging of the vasculature over a period of 1 hr. Therefore, no operator dependent timing of image acquisition is required after contrast agent injection. The additional advantage of using this contrast agent is that it is a small molecule (molecular weight 857 Da)¹⁸ and can permeate the sides of even a fully occluded thrombus, thereby providing excellent contrast of the DVT from surrounding areas on the MRV and enabling quantitative computation of DVT volumes. Previous studies have established the inter-rater reliability of visualizing veins using the MR Volume Interpolated Breath-hold Examination (VIBE) venography using gadofosveset trisodium¹⁹. Here, we use a similar approach in a multicenter clinical trial setting to evaluate deep vein thrombosis and use the volume of DVT measured by MRI as an endpoint. eTRIS provides an ideal platform to evaluate the feasibility and reproducibility of analysis of the MRV imaging approach proposed here, using a long-circulating Gd-based blood pool contrast agent for evaluating DVT volumes. We also evaluate the use of a direct thrombus imaging (DTHI) approach to quantify the extent of fresh DVT prior to the injection of contrast agents.

Two MRI examinations were performed during the course of the study: the first within 36 hr after randomization into the edoxaban monotherapy group or heparin/warfarin group, and the second between 14 to 21 days after randomization. The analyses of all the images were performed by a centralized core laboratory. Volume of fresh thrombus is calculated from a Direct Thrombus Imaging (DTHI) in the legs and lower pelvis before the injection of any contrast agent. The total thrombus volume (fresh and old) is computed from a post contrast magnetic resonance venography (MRV) images of the veins in the legs and lower pelvis.

Protocol

This study was approved by the local institutional review boards at all participating centers. All subjects in the multicenter trial provided written informed consent to participate in eTRIS at their respective institutions.

1. Image Acquisition

1. Perform the MR imaging on a 1.5 T or 3 T whole body scanner using specialized phased-array coils for MRV such as a peripheral vascular coil, body matrix coils or run-off coils. Use these coils in conjunction with other body matrix coils or spine coils. If no suitable specialized coils are available, use the body coil instead.
   NOTE: Use commercially available scanners such as Siemens Symphony, Sonata, etc.
   1. Screen subject, and review MRI safety questionnaire prior to scan. Have subject change into a gown.
2. Place an intravenous line in the antecubital vein of subject for the injection of the contrast agent. Follow standard safety procedures for injecting a gadolinium-based contrast agent.
3. Place subject in supine, feet first position in the MRI machine and position appropriate coils on regions to be scanned. Secure coils using Velcro straps as needed.
   1. Fasten subject’s legs/feet to prevent motion artifacts during the MRI scan.
   2. Turn on the centering laser and move the table until the laser crossbeams are located just below the subject’s knees (patella). Accept this position for the iso-center of the scan and move the patient table to the center position of the scanner bore.
4. Measure the creatinine clearance (CrCL) and determine the dose of the contrast agent to be used for the subject based on body weight. If CrCL <30 ml/min, subject is excluded from the study. For individuals with CrCL >30 ml/min but less than 45 ml/min, 0.01 mmol/kg of contrast agent is used. For individuals with CrCL >45 ml/min but <60 ml/min, 0.02 mmol/kg of gadofosveset is injected. For individuals with normal renal function (creatinine clearance >60 ml/min), a dose of 0.03 mmol/kg (0.12 ml/kg) gadofosveset trisodium is used. An MRI compatible power injector is used to inject the contrast agent.
5. Perform bilateral imaging of both legs and lower pelvis in a single examination session lasting approximately 60 min as shown in Table 1 and described in MRI protocol section.
   NOTE: Anonymize patient data prior to transfer of images to a central core laboratory for analysis.

2. MRI Protocol

1. Execute the imaging protocol from the scanner console by selecting each protocol step from the protocol window and dragging it to the execution list. Once ready, run the sequence by pressing Scan/Execute or equivalent button.
2. Acquire 2D gradient echo based sequences using sequence parameters in Table 1, in the three orthogonal axes to image from mid-calf to above the iliac crest and use as localizers/scouts.
3. Perform time of flight (TOF) angiography scans in each segment as specified in Table 1
   NOTE: These scans are also used as localizers to help differentiate arteries from veins as a long circulating contrast agent is used in steady state in this protocol. This view of the arterial tree is quite limited and only serves to help the image analyst differentiate the arteries from the venous vasculature and does not serve as a full-fledged angiogram.
4. To avoid acquiring poor quality images at the inferior and superior extent of the imaging volume, acquire three coronal 40 cm segments in the foot to head direction overlapping by 10 cm during the 3D T1-weighted Gradient Echo scans.
   NOTE: These three segments encompass: a) mid-calf to above knee b) above knee to thigh/lower pelvis, and c) thigh/pelvis to abdomen. Figure 1 shows sample images with the three acquisition locations illustrated.
5. To distinguish between acute and chronic venous thrombosis, acquire T1W direct thrombus imaging (DTHI) and 3D gradient echo (GRE) sequences using parameters in Table 1.
   NOTE: These 3 scans also serve as the pre-contrast scan for the MRV acquisition. The extent of the coverage of these acquisitions is the same as the initial localizers acquired in the three locations illustrated in Figure 1. GRE sequence is also easily implementable on various scanning platforms and across imaging field strengths.

Figure 1: Sample images showing acquisition locations for the 3 stations used for imaging. The field of view in the coronal direction and axial directions was 40 cm for each bed position [acquisition: (mid-calf to above knee), (above knees to thigh/pelvis), (thigh/pelvis to abdomen)] with 10 cm overlap between each bed position. (a) axial image; (b) sagittal image and (c) coronal image. Red arrow indicates DVT. Please click here to view a larger version of this figure.

6. Administer the contrast agent (gadofosveset trisodium) at a dose of 0.03 mmol/kg (0.12 ml/kg) intravenously into the subject at a rate of 2 ml/sec and flush with 20 ml of saline. Let the contrast agent circulate for 5 min to ensure a steady state in the blood pool.
7. Acquire MRV images; post contrast 3D gradient echo sequences at 3 locations described previously. See the sequence parameters in Table 1 and Table 2. Use these images to determine the locations and size of the thrombi.

Table 1: Lower extremity MR venography protocol with the contrast agent, gadofosveset trisodium, including direct thrombus imaging.

Table 2: The specific imaging parameter for each sequence acquired in the protocol.

8. After scan is completed, remove subject from the MRI scanner and take out the intravenous line. Ask the subject to change out of gown and exit the facility.

3. Image Analysis

1. Perform image analysis on a dedicated image analysis workstation running FDA-approved open source image processing software such as OsiriX MD²⁰, by 2 trained image analysts. Ensure the analysts have a minimum of 3 years experience each.
2. Temporarily blind all images before transfer to the image analyst workstation for analysis.
3. Ensure that a radiologist assesses each MRI scan for the presence and location of thrombi. Provide the radiologist’s assessment to the image analyst to be used as a guideline throughout the analysis.
4. Load all DICOM images from both MRI visits of a subject into the image processing software by selecting “import”, and compare the two imaging time-points of the MRV series for each subject to ensure adequate spatial coverage and registration across time points.
   1. Select the “3D MPR” tool in viewer to provide simultaneous browsing of image data in 3 orthogonal views (axial, coronal, and sagittal).
      NOTE: The image processing software’s 3D MPR mode enables the viewing of the vessels of interest.
5. Analyze the following vessels if DVT is present: external iliac, common femoral, superficial femoral, deep femoral, popliteal, anterior tibial, posterior tibial I & II, gastrocnemius I & II, and peroneal I & II veins. All analysis is restricted to regions of the vessels that are present in images from both time-points.
6. Assess the quality of the image for each vein with known DVT as indicated by the radiologist’s assessment on a 0-5 scale, with 0-2 being unanalyzable and 3-5 being analyzable for both the DTHI and MRV sequences. For the breakdown of scoring system see Figure 2.

Figure 2: The breakdown of the scoring system used for assessing the quality of images for each vein of interest with known DVT.

7. For MRV analysis, analyze each vessel individually. After 3D curved multiplanar reconstruction, use contours following the centerline of each vein, traced by the analyst, to generate curved path for each vein and save to file.
   1. Establish the position of the thrombus in the three dimensional space. From the Curved MPR plane, a 3D Bezier path will be displayed.
   2. Delineate the centerline of the vein by selecting of the “Contour Path” tool in “Creation Mode”.
   3. Place points repeatedly on any of the orthogonal MPR view to straighten the entire vessel of interest.
   4. Make adjustments when necessary to ensure that the vessel is entirely straightened in “Editing Mode”
   5. When the contour path is accurately delineated at centerline of vessel, save by selecting the “curved path” icon to export the file
   6. Generate 1 mm axial slices perpendicular to the curved path and save as DICOM files (Figure 3). Observe the the curved path, straightened vessel, and corresponding axial images for quantifying DVT from MRV images.
      NOTE: The images rendered in the 3D Curved MPR viewer must then be exported in DICOM format and added to the database as a new series of images.

Figure 3: Sample DVT shown on MRV sequence. (i, left panel) Curved path (yellow line) illustrates the contour followed by the vein being analyzed. (ii, middle panel) Straightened vessel along centerline of vessel being analyzed (red dotted line) (iii, right panel) shows axial slices perpendicular to vein being analyzed at locations indicated by yellow lines (A, B, C) on longitudinal sections. Please click here to view a larger version of this figure.

7. 7. On these axial DICOM images, manually segment regions of interest encompassing the thrombus (see Figure 4) by using the “Closed Polygon ROI Tool”. Save regions of interests to file by selecting the “Save all ROIs of this Series” located in the “ROI” drop down menu and save ROI metrics by navigating to the the “Plugins” menu and select “ROI Tools” followed by “Export ROIs”. This should be saved in a CSV format.

Figure 4: Manually segmented regions of interest (green) are shown encompassing the thrombus on axial reformatted DICOM images. Please click here to view a larger version of this figure.

7. 8. Calculate thrombus volume by multiplying the area on each analyzed slice by the slice thickness (1 mm) using a custom built Matlab script. Calculate total thrombus volume in each subject by adding the thrombus volumes in each vessel.
8. For DTHI analysis, identify fresh thrombus as bright regions on pre-contrast T1W 3D gradient echo scans¹³ within the DVT regions segmented by the MRV.
   1. On axial pre-contrast images, compute the volume of fresh thrombus by drawing regions of interest (ROI) manually as shown in Figure 5. In Figure 6, sample images indicating DVT measured by DTHI in conjunction with the MRV images are depicted.
   2. Open the pre-contrast and post-contrast sequences alongside each other. Select “axial” view and delineate bright regions along the vessel of interest using the “closed polygon ROI Tool”.

Figure 5: Sample DVT shown on DTHI imaging sequence. (a) coronal image, (b) axial image, and (c) axial image showing region of interest (green) traced around fresh thrombus (blue arrows) on pre-contrast images. The DTHI images are acquired prior to the injection of contrast agent and rely on met-hemoglobin content of thrombus to produce bright signal.

Figure 6: Sample DVT shown on DTHI imaging sequence. The left panels show MRV images with signal voids indicating total DVT (green arrows). The right panel show corresponding DTHI images with bright signal indicating presence of fresh thrombus (blue arrows). Please click here to view a larger version of this figure.

4. Assessment of Reproducibility

1. Evaluate a subset of ten subjects for the reproducibility of the analysis.
2. Perform analysis, as described above, by two separate image analysts (primary and secondary readers) to assess inter-observer variability
3. Ensure that primary reader also performs a second image analysis three months after the first analysis to assess intra-observer variability of the results.
4. Compute intra-class-correlation coefficients (ICC) and perform a Bland-Altman analysis to assess inter and intra-observer reproducibility. Carry out a one sample t-test to look for bias on Bland-Altman analysis. ICC >0.9 and no bias on Bland-Altman analysis are considered acceptable.

Results

For the purpose of the reproducibility assessments, the baseline and follow up scans were pooled and analyzed as separate cases. From the 10 randomly selected subjects (2 visits each), there were 59 vessels with DVT identified using the MRV approach and 29 vessels with fresh thrombus identified by the DTHI. In the subset of these 10 randomly selected subjects analyzed for the reproducibility metrics, no vessels with DVT were deemed to be of un-analyzable quality (defined as subjective scoring 0-2 for both MRV and DTHI im...

Discussion

This study demonstrated the feasibility of quantification of deep vein thrombosis on MR venography using gadofosveset trisodium as a contrast agent, with excellent reproducibility of analysis for quantifying thrombus volume in a multicenter setting. To compute total thrombus volume, the primary method utilized the post-contrast MRV scan to measure thrombus volume. The secondary method used was the direct thrombus imaging approach (DTHI), which leverages the presence of met-hemoglobin within a fresh thrombus to produce a ...

Materials

List of materials used in this article

Name	Company	Catalog Number	Comments
Ablavar (gadofosveset trisodium)	Lantheus		Contrast Agent
1.5 T or 3 T Scanners	GE, Siemens, or Phillips		GE (Horizon, Signa, Hdx, 750), Siemens (Symphony, Avanto, Sonata, Trio, Aera) or Philips (Intera, Achieva)